Platform adopted by 10 of the top 25 biopharmaceutical companies, by U.S. governmental agencies, and by academic research centers worldwide Organs-on-Chips enable drug developers and researchers to ...

Emulate is the leading provider of next generation in vitro biological models. Researchers use their organ-on-a-chip technology to understand and predict drug response with greater precision and ...

The human guinea pig may soon be extinct. He (it’s usually a ‘he’) has become endangered through the advances of cell culture science, which increasingly close the gap between in vitro testing (the ...

Emulate, Inc. today announced the company’s launch with a $12 million Series A financing to commercialize a first-in-kind, automated ‘Organs-on-Chips’ platform that mimics human physiology and ...

Recent pre-clinical studies confirm predictable, specific and statistically significant effects in multiple biological models. BELLEVUE, WA / ACCESSWIRE / February 15, 2022 / EMulate Therapeutics, Inc ...

Emulate, Inc., the world leader in Organ-on-a-Chip technology, today announced the commercial launch of the AVA™ Emulation System , a self-contained instrument that cultures, incubates, and images up ...

Emulate has raised $82 million in a series E round to help further develop and commercialize its organ-on-a-chip technology. The Boston, MA company has raised a total of $225 million since it was ...

This article was first published in the May 2016 issue of WIRED magazine. Be the first to read WIRED's articles in print before they're posted online, and get your hands on loads of additional content ...

BOSTON--(BUSINESS WIRE)--Emulate, Inc., today announced that Jim Corbett has been appointed as Chief Executive Officer and Martin Madaus, Ph.D., has been appointed Executive Chairman of the company’s ...

Emulate Inc., a biotech company focused on developing “organ-on-a-chip” technology, closed an $82 million Series E round on Tuesday. This latest round is intended to formulate a massive investment in ...